- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT03869736
Nitrous Oxide for the Treatment of Major Depressive Disorder
Evaluation of the Antidepressant Effects of Nitrous Oxide in People With Major Depressive Disorder
The investigators are conducting a randomized controlled trial to evaluate the antidepressant effects of nitrous oxide in people with Major Depressive Disorder (MDD). MDD is a global medical condition that causes significant health and economic burden. Recent studies have shown that a single dose of ketamine, an NMDA-antagonist, has fast and long lasting anti-depressant effect. Nitrous oxide, another NMDA-antagonist, is widely used for anesthesia and analgesia, safer to administer and has fewer side effects than ketamine.
A randomized controlled crossover feasibility study showed significant reduction in depressive symptoms at 2 and 24 hours after a single 1-hour treatment session of inhaled nitrous oxide compared with placebo. Nitrous oxide is inexpensive and can be safely administered by any trained clinician. If found to be efficacious, it could be used to provide rapid anti-depressant effect whilst the benefit of traditional anti-depressants has its delayed effect. Another potential application could be in acutely suicidal patients.
This investigated-initiated phase 2b trial will enable confirmation and extension of the findings from the feasibility study, and identify the optimal dose and regimen in a broader population of those with MDD. Participants will be randomized to receive a weekly 1-hour inhalational sessions of either nitrous oxide or placebo (oxygen-air mixture) for 4 weeks, and the nitrous group will be further randomly assigned to a dose of 50% nitrous oxide or 25% nitrous oxide. Depression severity will be assessed by a blinded observer pre-treatment and at weekly intervals during and for 4 weeks after treatment using the Hamilton Depression Rating Scale.
Study Overview
Status
Conditions
Intervention / Treatment
Study Type
Enrollment (Anticipated)
Phase
- Phase 2
Contacts and Locations
Study Contact
- Name: Carolyn Deng, MBChB
- Phone Number: +61399030760
- Email: c.deng@alfred.org.au
Study Contact Backup
- Name: Sophie Wallace, MPH
- Phone Number: +61 3 90762651
- Email: s.wallace@alfred.org.au
Study Locations
-
-
Victoria
-
Melbourne, Victoria, Australia, 3004
- Recruiting
- Alfred Hospital
-
Contact:
- Sophie Wallace, MPH
- Phone Number: +61 3 90762651
- Email: s.wallace@alfred.org.au
-
Contact:
- Paul Myles, MD, DSc
- Phone Number: +61390763176
- Email: p.myles@alfred.org.au
-
-
-
-
Illinois
-
Chicago, Illinois, United States, 60637
- Not yet recruiting
- University of Chicago Medicine
-
Contact:
- Peter Nagele, MD, MSc
- Email: pnagele@dacc.uchicago.edu
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Adult (≥18 years, both sexes), with DSM-IV-TR criteria for MDD without psychosis, as determined using a structured clinical interview [Mini International Neuropsychiatric Interview]
- MDD, as defined by a pretreatment score >18 on the HDRS-21 scale
Exclusion Criteria:
- A history of bipolar disorder, schizophrenia, schizoaffective disorder, obsessive-compulsive disorder, panic disorder, or documented Axis II diagnoses; active suicidal intention, as determined by clinical interview
- Active or recent (<12 months) substance abuse or dependence; excluding nicotine
- Administration of NMDA-antagonists (e.g., ketamine) in previous 3 months
- Ongoing treatment with ECT
- Presence of acute medical illness that could interfere with study participation, including significant pulmonary disease
- Pregnancy or breastfeeding
- Any contraindications to the use of nitrous oxide (e.g., pneumothorax, middle ear occlusion, elevated intracranial pressure, chronic cobalamin or folate deficiency unless treated with folic acid or vitamin B12).
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Double
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Nitrous Oxide 50% or 25%
Nitrous oxide at an inhaled concentration of 50% or 25%
|
1-hour sessions of inhaled nitrous oxide at concentrations of 25% or 50% (randomly assigned) to be administered weekly for 4 weeks.
|
Sham Comparator: Placebo
Oxygen-air mixture
|
1-hour sessions of inhaled oxygen-air mixture (inspired oxygen concentration ~23-30%) to be administered weekly for 4 weeks.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Change in HDRS-21 score
Time Frame: over 4 weeks from baseline
|
21-point Hamilton Depression Rating Scale Interview-based questionnaire used to measure the severity of depression. Consists of 21 items with a score calculated from the first 17 answers. Higher scores are associated with more severe depression: 0 - 7 = Normal 8 - 13 = Mild Depression 14-18 = Moderate Depression 19 - 22 = Severe Depression > 23 = Very Severe Depression Max score = 52 |
over 4 weeks from baseline
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Treatment response and remission
Time Frame: at 24 hours
|
Treatment response (≥50% reduction on HDRS-21) and remission (HDRS-21 ≤7 points), nitrous oxide vs. placebo
|
at 24 hours
|
Pattern of treatment response
Time Frame: Up to 1 week after treatment
|
Assessed using daily Profile of Mood States scale. The POMS measures six different dimensions of mood swings over a period of time. score range with lower scores indicative of people with more stable mood profiles The Profile of Mood States (POMS) questionnaire is a validated psychological test containing 65 emotions/ mood states. Participants are asked to rank their current mood states using the scale 'not at all', 'a little', 'moderately', 'quite a lot' or 'extremely'. Total Mood Disturbance (TMD) score and an analysis of tension, depression, anger, vigour, fatigue and confusion is performed based on the participants mood states. Total Mood Disturbance (TMD) can be calculated by adding the scores for Tension, Depression, Anger, Fatigue and Confusion and then subtracting the score for Vigour. • TMD = (Tension + Depression + Anger + Fatigue + Confusion) - Vigour |
Up to 1 week after treatment
|
Sustainability of treatment response - change in HDRS-21 scores
Time Frame: over 7 weeks
|
Change in the HDRS-21 score, nitrous oxide vs placebo HDRS-21 is an interview-based questionnaire used to measure the severity of depression. Consists of 21 items with a score calculated from the first 17 answers. Higher scores are associated with more severe depression: 0 - 7 = Normal 8 - 13 = Mild Depression 14-18 = Moderate Depression 19 - 22 = Severe Depression > 23 = Very Severe Depression Max score = 52 |
over 7 weeks
|
Sustainability of treatment response - response and remission rates
Time Frame: over 7 weeks
|
Response and remission rates (%), nitrous oxide vs placebo
|
over 7 weeks
|
Treatment compliance rate
Time Frame: over 4 weeks
|
Refusal or inability to attend further treatments, nitrous oxide vs placebo
|
over 4 weeks
|
Dose effect of nitrous oxide using treatment-by-dose interaction term in a logistic regression model
Time Frame: over 7 weeks
|
Dose effect of nitrous oxide at 25% and 50% using a treatment-by-dose (group) interaction term in a logistic regression model to assess for statistical significance.
|
over 7 weeks
|
Computerized Adaptive Test-Depression Inventory (CAT-DI)
Time Frame: over 7 weeks
|
Adaptive testing questionnaire that assesses severity, likelihood and percentile of depression based on an average of 12 items administered from a question bank of 400 items.
Questions are adapted to the participants answers and targeted to their level of impairment.
Results generate include: severity of depression (normal, mild, moderate, severe), likelihood of depression (out of probability of 1), percentile of severity.
|
over 7 weeks
|
Computerized Adaptive Test-Suicide Scale (CAT-SS)
Time Frame: over 7 weeks
|
Adaptive testing questionnaire that assesses risk and severity of suicide based on items administered from a question bank.
Questions are adapted to the participants answers and targeted to their level of impairment.
Results generate include: risk of suicide (low, intermediate, high) and a percentile of risk.
|
over 7 weeks
|
Other Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Adverse events
Time Frame: over 7 weeks
|
Psychiatric AEs, such as new suicidal ideation and psychotic symptoms Other AEs, such as cardiorespiratory AEs or nausea and vomiting
|
over 7 weeks
|
Collaborators and Investigators
Sponsor
Investigators
- Principal Investigator: Paul Myles, MD, The Alfred
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Anticipated)
Study Completion (Anticipated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Estimate)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
- Behavioral Symptoms
- Mental Disorders
- Pathologic Processes
- Mood Disorders
- Depression
- Depressive Disorder
- Disease
- Depressive Disorder, Major
- Physiological Effects of Drugs
- Central Nervous System Depressants
- Peripheral Nervous System Agents
- Analgesics
- Sensory System Agents
- Anesthetics, General
- Anesthetics
- Analgesics, Non-Narcotic
- Anesthetics, Inhalation
- Nitrous Oxide
Other Study ID Numbers
- 438/19
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
product manufactured in and exported from the U.S.
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Depression
-
ProgenaBiomeRecruitingDepression | Depression, Postpartum | Depression, Anxiety | Depression Moderate | Depression Severe | Clinical Depression | Depression in Remission | Depression, Endogenous | Depression ChronicUnited States
-
Washington University School of MedicineCompletedTreatment Resistant Depression | Late Life Depression | Geriatric Depression | Refractory Depression | Therapy-Resistant DepressionUnited States, Canada
-
University of California, San FranciscoRecruitingDepression Moderate | Depression Mild | Depression, TeenUnited States
-
University GhentUniversiteit Antwerpen; Janssen-Cilag Ltd.RecruitingDepression Moderate | Depression Severe | Depression MildBelgium
-
Baylor College of MedicineUniversity of TexasRecruitingDepression | Depression Moderate | Depression Severe | Suicide and Self-harm | Depression in Adolescence | Depression MildUnited States
-
University of Cape TownNational Institute of Mental Health (NIMH)CompletedPostpartum Depression | Clinical Depression | Moderate DepressionSouth Africa
-
Washington University School of MedicinePatient-Centered Outcomes Research Institute; National Institute of Mental...CompletedMajor Depressive Disorder | Treatment Resistant Depression | Treatment-Refractory Depression | Late Life Depression | Geriatric DepressionUnited States, Canada
-
Northern Illinois UniversityUniversity Autonoma de Santo DomingoTerminatedDepression Moderate | Depression MildUnited States, Dominican Republic
-
Gerbera Therapeutics, Inc.Not yet recruitingPostpartum Depression | Depression, Postpartum | Postnatal Depression | Post-partum Depression | Post-Natal DepressionUnited States
-
Lawson Health Research InstituteTerminated
Clinical Trials on Nitrous Oxide
-
University of ChicagoNational Institute on Drug Abuse (NIDA)CompletedSubstance-Related Disorders | Opioid-Related DisordersUnited States
-
State University of New York at BuffaloCompleted
-
Washington University School of MedicineBrain & Behavior Research FoundationCompletedDepressive Disorder, Major | Depressive Disorder, Treatment-ResistantUnited States
-
Beth Israel Deaconess Medical CenterRecruitingProcedural Pain | Pain Catastrophizing | Procedural AnxietyUnited States
-
Beth Israel Deaconess Medical CenterBoston Children's HospitalCompletedLower Urinary Tract SymptomsUnited States
-
Beth Israel Deaconess Medical CenterBrigham and Women's HospitalCompletedPain | Benign Prostatic Hyperplasia | Prostate Cancer | Prostate Adenocarcinoma | Anxiety and Fear | Malignancy | Prostate DiseaseUnited States
-
Washington University School of MedicineFoundation for Anesthesia Education and ResearchCompletedCardiovascular AbnormalitiesUnited States
-
National Institute of Diabetes and Digestive and...CompletedAvitaminosis | Delirium, Dementia, Amnestic, Cognitive DisordersUnited States
-
University of ChicagoNational Institute on Drug Abuse (NIDA)CompletedSubstance-Related Disorders | Opioid-Related DisordersUnited States
-
Baxter Healthcare CorporationCompleted